#1 Clinical Trials Search in Europe

Vibrio Alginolyticus Collagenase

This article discusses the ongoing clinical trials investigating the use of Vibrio Alginolyticus Collagenase as a potential treatment for Dupuytren’s contracture. The study is designed as a Phase I/II trial to evaluate the safety, efficacy, and optimal dosing of this new medication for patients suffering from this hand condition. The trials aim to provide valuable insights into the potential benefits and risks of using this bacterial collagenase to treat Dupuytren’s contracture, offering hope for a new non-surgical treatment option.

Table of Contents

What is Vibrio Alginolyticus Collagenase?

Vibrio Alginolyticus Collagenase is a new medication being studied for the treatment of Dupuytren’s contracture. It is a type of enzyme (a protein that speeds up chemical reactions in the body) that comes from a bacteria called Vibrio alginolyticus[1]. This enzyme is designed to break down collagen, a protein that makes up the tough cords in Dupuytren’s contracture.

What is Dupuytren’s Contracture?

Dupuytren’s contracture is a hand condition where thick, tough tissue forms under the skin of the palm and fingers. Over time, this tissue can form cords that pull one or more fingers into a bent position. This can make it hard to straighten your fingers or use your hand normally[1].

How Vibrio Alginolyticus Collagenase Works

Vibrio Alginolyticus Collagenase is injected directly into the cord causing the contracture. The enzyme works by breaking down the collagen in the cord. This can help to weaken and eventually break the cord, allowing the affected finger(s) to straighten[1].

Current Research and Clinical Trials

A Phase I/II clinical trial is currently underway to study the safety and effectiveness of Vibrio Alginolyticus Collagenase for treating Dupuytren’s contracture. This study is divided into two parts[1]:

  1. Phase I: This part aims to find the highest safe dose of the medication.
  2. Phase II: This part will test how well the chosen dose works compared to a placebo (a harmless substance with no active ingredients).

The study is looking at several important factors[1]:

  • How many patients achieve “clinical success” (defined as a reduction in contracture to 5° or less) after treatment
  • How many injections are needed to achieve this success
  • How long the effects of the treatment last
  • How safe the treatment is and what side effects it might have

Potential Benefits

If successful, Vibrio Alginolyticus Collagenase could offer several benefits for patients with Dupuytren’s contracture[1]:

  • Non-surgical treatment option: This could be less invasive than surgery.
  • Potential for multiple treatments: The study is looking at the effects of up to three injections.
  • Improved hand function: The goal is to reduce the contracture, which could improve the ability to use the hand normally.
  • Long-lasting effects: The study is following patients for up to 6 months to see how long the benefits last.

Safety and Side Effects

A major focus of the current study is to evaluate the safety of Vibrio Alginolyticus Collagenase. While specific side effects are not yet known, the researchers are carefully monitoring for any adverse reactions[1]. They are also checking if patients develop antibodies to the medication, which could affect its long-term use.

Eligibility for Treatment

The current study has specific criteria for who can participate. These include[1]:

  • Adults 18 years or older
  • Diagnosed with Dupuytren’s contracture with a fixed flexion deformity of 20° to 100° in a knuckle joint (MP) or 20° to 80° in a finger joint (PIP)
  • No previous treatments for Dupuytren’s contracture (with some exceptions)
  • No history of bleeding disorders or current use of blood thinners (except for low-dose aspirin)

It’s important to note that these criteria are for the research study and may not reflect future treatment eligibility if the medication is approved.

Future Prospects

Vibrio Alginolyticus Collagenase is still in the research phase and is not yet available as a standard treatment. The results of this study will help determine if it’s safe and effective for treating Dupuytren’s contracture. If successful, it could provide a new option for patients with this condition[1].

As with any new treatment, it’s important to discuss the potential risks and benefits with your healthcare provider. They can provide the most up-to-date information and help you make informed decisions about your care.

Aspect Details
Study Type Phase I/II clinical trial
Drug Vibrio Alginolyticus Collagenase
Condition Dupuytren’s contracture
Primary Objectives Evaluate safety, tolerability, and efficacy of the drug
Study Design Two parts: Phase I (dose escalation) and Phase II (randomized, placebo-controlled)
Main Outcome Measure Proportion of patients achieving clinical success (contracture reduction to ≤5°)
Secondary Outcomes Clinical improvement, time to success, range of motion changes, pharmacokinetics, immunogenicity
Eligibility Adults with Dupuytren’s contracture (≥20° and ≤100° for MP joint, or ≥20° and ≤80° for PIP joint)
Follow-up Up to 6 months after last injection

FAQ

  • What is Dupuytren's contracture? Dupuytren's contracture is a hand condition that causes one or more fingers to bend towards the palm. It occurs when tissue in the palm thickens and forms cords that pull the fingers inward, limiting hand function.
  • How does Vibrio Alginolyticus Collagenase work in treating Dupuytren's contracture? Vibrio Alginolyticus Collagenase is an enzyme that breaks down collagen, the main component of the cords in Dupuytren's contracture. When injected into the affected cord, it may help to weaken and break it, potentially allowing the contracted finger to straighten.
  • What are the main objectives of this clinical trial? The main objectives are to evaluate the safety and tolerability of different doses of the collagenase, identify the maximum tolerated dose, and assess its effectiveness in reducing finger contracture compared to a placebo.
  • Who is eligible to participate in this clinical trial? Eligible participants are adults (18 years or older) with a diagnosis of Dupuytren's contracture causing a fixed flexion deformity in at least one finger (excluding the thumb). The contracture must be caused by a palpable cord that could benefit from collagenase treatment.
  • How is the effectiveness of the treatment measured in this trial? The effectiveness is primarily measured by the proportion of patients who achieve 'clinical success,' defined as a reduction in contracture to 5 degrees or less within 30 days after the last injection. Other measures include the degree of contracture reduction, range of motion improvement, and time to achieve clinical success.

Ongoing Clinical Trials on Vibrio Alginolyticus Collagenase

  • Study on the Safety and Effectiveness of Vibrio Alginolyticus Collagenase and Alprostadil for Patients with Peyronie’s Disease

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Safety and Effectiveness of Vibrio Alginolyticus Collagenase for Patients with Dupuytren’s Contracture

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany Italy Sweden

Glossary

  • Dupuytren's contracture: A hand condition where tissue in the palm thickens and forms cords, causing one or more fingers to bend towards the palm.
  • Collagenase: An enzyme that breaks down collagen, a protein found in connective tissues.
  • Clinical success: In this study, it refers to a reduction in contracture to 5 degrees or less after treatment.
  • Contracture: A condition of shortening and hardening of muscles, tendons, or other tissue, often leading to deformity or rigidity of joints.
  • Palpable cord: A thickened strand of tissue that can be felt under the skin, characteristic of Dupuytren's contracture.
  • Goniometry: The measurement of joint angles, used to assess the degree of contracture and range of motion.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body.
  • Anti-drug antibodies: Antibodies produced by the immune system in response to a therapeutic drug.
  • Maximum tolerated dose: The highest dose of a drug that does not cause unacceptable side effects.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-vibrio-alginolyticus-collagenase-for-patients-with-dupuytrens-contracture/